Anticancer peptide PNC-27 shows dose-dependent growth inhibition and cytotoxicity in primary human ovarian cancer cells.
Background
Despite an initial 80% response rate to chemotherapy, epithelial ovarian cancer carries the highest case fatality rate among all gynecologic malignancies. A primary challenge is the development of resistance to standard chemotherapies, leading to recurrence and poor long-term outcomes. This has created a critical need for alternative therapeutic strategies that can effectively target both newly diagnosed and treatment-resistant cancers. Anticancer peptides like PNC-27 represent a novel approach, with previous studies indicating their ability to selectively kill various cancer cells both in vitro and in vivo. This study investigates PNC-27's potential as a direct treatment for primary, patient-derived ovarian cancer cells.
Study Design
Researchers established primary cell cultures from freshly isolated tumors of patients with newly diagnosed ovarian cystadenocarcinomas. Two specific lines were developed: one from a mucinous cystadenocarcinoma and another from a high-grade papillary serous carcinoma. These cells were treated with the anticancer peptide PNC-27 in a dose-dependent manner. A control peptide, PNC-29, was used as a negative control. The study also included established, chemotherapy-resistant human ovarian cancer cell lines. Treatment effects were assessed qualitatively via light microscopy and quantitatively using the MTT cell proliferation assay to measure growth inhibition and a lactate dehydrogenase (LDH) assay to measure direct cytotoxicity.
Results
The study found that PNC-27 successfully inhibits the growth of and is cytotoxic to freshly isolated primary human epithelial ovarian cancer cells. The effects were observed in a dose-dependent fashion, meaning higher concentrations of the peptide resulted in greater cancer cell death. Furthermore, PNC-27 was also cytotoxic to long-established human ovarian cancer cell lines known for their resistance to conventional chemotherapy.
In contrast to the potent effects of the active peptide, the control peptide PNC-29 demonstrated no effect on the primary cancer cells, confirming the specific anticancer activity of the PNC-27 sequence.
This is the first reported evidence of PNC-27's efficacy on primary, patient-derived cancer cells that had not been previously exposed to treatment. The results highlight the peptide's ability to target both treatment-naive and chemo-resistant ovarian cancer phenotypes.
Key Findings
- PNC-27 inhibits growth of primary human ovarian cancer cells in a dose-dependent manner.
- PNC-27 is cytotoxic to freshly isolated human epithelial ovarian cancer cells.
- The control peptide, PNC-29, had no effect on the primary cancer cells.
- PNC-27 is also cytotoxic to established, chemotherapy-resistant human ovarian cancer cell lines.
- This is the first study to show PNC-27's efficacy on freshly isolated, primary human cancer cells.
Why It Matters
These ex vivo findings suggest PNC-27 could be a valuable therapeutic agent for ovarian cancer, a disease with high mortality despite initial chemo-responsiveness. The peptide’s effectiveness against both newly diagnosed and chemotherapy-resistant cells is particularly significant, as it could address the major clinical challenge of tumor recurrence and drug resistance. For clinicians and researchers, this provides a strong rationale for advancing PNC-27 into further preclinical and eventually clinical trials. This positions PNC-27 as a potential standalone treatment or as an adjunct to current protocols, especially for patients who have failed standard chemotherapy. While promising, this is early-stage research using patient cells in a lab setting; it is far from establishing a human-usable protocol.
pnc-27
pnc-29
ovarian cancer
epithelial ovarian cancer
oncology
anticancer peptide
